J9

Glucocorticoid resistance inhibitor

Product Type: Inhibitor

MolecularFormula: C12H12N4

Molecular Weight: 212,26

Source: Synthetic

Purity: 99.9%

Solubility: Soluble in CDCI3

Appearance: White Solid

PubChem CID: PMC4094258

Scientific Background: J9, in combination with dexamethasone inhibits cell growth in T-cell acute lymphoblastic leukemia (T-ALL) through the upregulation of the glucocorticoid receptor. Patients can develop glucocorticoid resistance rendering the treatment ineffective. J9 and its mechanism of action provides a useful strategy for overcoming the resistance. The EC50 of J9 in combination with dexamethasone is 28 uM. J9 alone was less toxic.

References: 1. Cantley A.M., et al. (2014) ACS Medicinal Chemistry Letters 5.7: 754-759.

Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• Artikelnummer: STRSIH-182-10MG
• Hersteller: Stressmarq Biosciences
• Hersteller Artikelnummer: SIH-182-10MG
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK